Shopping Cart
Remove All
Your shopping cart is currently empty
JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. It downregulates the expression of p-STAT3 and p-STAT5 and exhibits good bioavailability. JAK2-IN-13 effectively suppresses recombinant human erythropoietin-induced extramedullary erythropoiesis as well as polycythemia vera. It is used in the study of myeloproliferative neoplasms.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. It downregulates the expression of p-STAT3 and p-STAT5 and exhibits good bioavailability. JAK2-IN-13 effectively suppresses recombinant human erythropoietin-induced extramedullary erythropoiesis as well as polycythemia vera. It is used in the study of myeloproliferative neoplasms. |
| Targets&IC50 | JAK2:54.7 nM |
| In vitro | JAK2-IN-13 (Compound 11) exhibits potent inhibitory activity against HEL and SET-2 cells at concentrations of 0.011-25 μM over 72 hours, with IC50 values of 0.57 μM and 1.07 μM, respectively. Additionally, JAK2-IN-13 (0-10 μM, 3 h) significantly inhibits the JAK2 downstream signaling pathway in HEL cells, reducing the expression of p-STAT3 and p-STAT5. |
| In vivo | JAK2-IN-13 (Compound 11) administered orally at 50-100 mg/kg once daily for 4 consecutive days, inhibited extramedullary erythropoiesis and polycythemia vera in the rhepo-induced erythrocytosis model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.